The two B-cell non-Hodgkin's lymphoma entities, chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), show recurrent chromosomal gains of 3q25-q29, 12q13-q14 and 18q21-q22. The pathomechanisms affected by these aberrations are not understood. The aim of this study was to identify genes, located within these gained regions, which control cell death and cell survival of MCL and CLL cancer cells. Blood samples collected from 18 patients with CLL and 6 patients with MCL, as well as 6 cell lines representing both malignancies were analyzed by gene expression profiling. By a comparison of genomic DNA and gene expression, 72 candidate genes were identified. We performed a limited RNA interference screening with these candidates to identify genes affecting cell survival. CCDC50 (coiled coil domain containing protein 50), SERPINI2 and SMARCC2 mediated a reduction of cell viability in primary CLL cells as well as in cell lines. Gene knockdown and a nuclear factor kappa B (NFjB) reporter gene assay revealed that CCDC50 is required for survival in MCL and CLL cells and controls NFjB signaling.
Introduction
Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are B-cell non-Hodgkin's lymphoma subtypes that share patterns of genetic aberrations. The median survival time of patients with MCL was reported to be 3-5 years after diagnosis. 1 A criterion for diagnosis of MCL is the translocation t(11;14)(q13;q32), resulting in the overexpression of the cyclin D1 gene. [2] [3] [4] [5] In addition to the t (11;14) , MCL carries a high number of secondary genetic alterations that may contribute to its pathogenesis. Several studies reported the high resolution detection of chromosomal imbalances in MCL using array comparative genomic hybridization, 6 accurately defining the gained regions. [7] [8] [9] [10] [11] [12] [13] However, these regions still contain too many genes to enable a reasonable selection of candidates, and it is not clear which genes have functional relevance for MCL. Recently, the incidence of genomic gains in t(11;14)(q13;q32)-positive MCL cases was assessed by fluorescence in situ hybridization analysis, revealing gains on 3q, 12q and 18q in 45, 17 and 14% of cases, respectively.
14 Candidate genes within these chromosomal regions have been proposed by various groups on the basis of profiling data acquired on different microarray platforms (single-nucleotide polymorphism array, array comparative genomic hybridization, expression array). [7] [8] [9] [10] [11] [12] [13] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Gains of genomic DNA may activate oncogenes through gene dosage effects, 20, 22 such as CDK4 (cyclin-dependent kinase-4) on 12q13 and B-cell lymphoma-2 (BCL2) on 18q21 in MCL. 1, 8, 11, 15, 18, 25 It was recently shown that highly proliferative and clinically aggressive variants of MCL have a complex karyotype with frequent gains on 3q and 12q. 11, 22, 26 Furthermore, the chromosomally gained region, 3q25-q29, shows an association with poor outcome in MCL patients. 22 Chronic lymphocytic leukemia is the most common leukemia among adults of the western world, with a variable survival time between ca. 3 and 20 years. CLL is characterized by the accumulation of mature, but resting B cells in peripheral blood, bone marrow and lymphatic or extralymphatic tissues. The majority of leukemic CLL cells are arrested in the cell cycle, mainly in the G0/G1 phase. 27, 28 Unlike other leukemias, there is only a small proportion of proliferating neoplastic cells that are localized in the so-called 'pseudofollicular' proliferation centers in the lymph nodes or are scattered in the bone marrow of the patients. 29, 30 The most frequently recurring chromosomal gain, identified in CLL patients, is trisomy 12. 27 The aim of this study was to identify genes with oncogenic potential in recurrently gained chromosomal regions of MCL and CLL. To this aim, gene expression profiling was performed, followed by cell survival and proliferation studies after silencing of candidate genes. First, we profiled the expression of 18 primary CLL, 6 primary MCL samples, as well as 6 cell lines, and compared all genes identified in the three gained regions (3q, 12q and 18q) with recently published data. Second, we investigated a set of 72 candidate genes derived from this analysis by the use of a small interfering RNA (siRNA)-mediated loss of function screen in a multiwell format in MCL cell lines. Third, we validated the observed changes in cell viability by gene knockdown in primary CLL cells and analyzed the downstream effects of the identified candidate gene, CCDC50 (coiled coil domain containing protein 50).
Materials and methods

Cell lines
Cell lines were obtained from DSMZ (Braunschweig, Germany) and from ATTC (American Type Culture Collection, Manassas, VA, USA). Granta (ACC 342), Mec-1 (ACC 497) and HEK-293T (Human embryonic kidney 293-T cells, CRL-1573) cells were cultured in DMEM (Dulbecco's modified Eagle's medium) (Invitrogen, Karlsruhe, Germany). JVM-2 (Human peripheral blood B-cell lymphoma cell line, ACC 12) and LCL-WEI (Human lympoblastoid B cells, ACC 218) were cultured in RPMI 1640 medium, including 2 mM L-glutamine (Invitrogen, Carlsbad, CA, USA). Both media were supplemented with 10% fetal calf serum and 1% penicillin/streptomycin.
Primary cells
Peripheral blood samples were collected from patients with CLL and MCL, as well as from healthy donors after informed consent was obtained from them (Supplementary Tables S1-S6 ). All cases matched standard diagnostic criteria. 31 The human bone marrow stromal cell line, HS-5, was purchased from the ATCC. Cells were cultured and prepared as published earlier. 32 
Nucleofection of cell lines and primary CLL cells
Using the Human B-cell Nucleofector Kit and program U-015, 5 Â 10 6 primary B cells were transfected with 500 nM siRNA (in 100 ml volume), according to the manufacturer's instructions (Lonza, Cologne, Germany). After nucleofection, primary cells were added to a sterile filtered conditioned medium, obtained from HS-5 cells, and cultured as published earlier. 32 Transfections of cell lines were performed by nucleofection (solution T, program O-017), according to the manufacturer's instructions, using 2 Â 10 6 cells and 2 mg DNA or 500 nM siRNA (in 100 ml volume). Cells were harvested 24, 48 and 72 h after transfection for RNA isolation and functional assays. Using 96-well Shuttle system with the 96-well Nucleofector Kit SF and program 96-DN-100, a total of 4 Â 10 5 cells of the cell lines JVM-2 or Granta-519 were transfected with 500 nM siRNA (in 20 ml volume), according to the manufacturer's instructions (Lonza).
Transfection of HEK-293T cells
A total of 4 Â 10 5 HEK-293T cells were transfected with 50 nM siRNA or 2.5 mg plasmid DNA using the TransIT transfection reagent, according to the manufacturer's instructions (Mirus Bio LLC, Madison, WI, USA).
Cloning of short hairpin coding plasmids
The plasmid pSUPERdL_Zeo was created by cloning the zeocin resistance gene, including an SV40 promoter and an SV40 polyA sequence, from the pTER plasmid 33 into the NotI and BamHI sites of pSUPERdL. 34 To obtain the PCR insert out of the pTER plasmid, the following primers were used: NotI_pTER_fw 5 0 -cgattgcggccgctgatttaac-3 0 and BamHI_pTER_rev 5 0 -cggaggatccaagctctagcta-3 0 . The sequence for cloning of a short hairpin of CCDC50 into the pSUPERdL_Zeo plasmid was designed according to the siRNA sequence for CCDC50 (Ambion Inc., Austin, TX, USA; 129979). Short hairpin sequences specific for CCDC50 are sh_CCDC50_sense: ATCCCCCCCTATGCTGCATATACTTTCAAGAGAAGTATATGC AGCATAGAGGTTTTTGGAAA and sh_CCDC50_antisense: AG CTTTTCCAAAAACCTCTATGCTGCATATACTTCTCTTGAAAGT ATATGCA GCATAGAGG. Cloning was performed as described previously, 34 and pSUPERdL_Zeo_sh_CCDC50 was sequenced. Stable transfection of the plasmid pSUPERdL_Zeo_sh_CCDC50 into the cell line Mec-1 and JVM-2 was performed by nucleofection. The transfected MCL cells were selected with 50 ng/ml zeocin. 
Western blot analysis
Transfected CLL cells were harvested by centrifugation (800 r.p.m., 10 min, room temperature). Cell pellets were lysed and protein extracts were purified using the All Prep RNA/ Protein Kit (Qiagen). Western blot analysis was carried out as published previously. 34 After immunoblotting, polyvinylidene fluoride membranes were probed with primary antibodies specific for CCDC50 (HPA001336, Sigma Aldrich, St Louis, MO, USA) and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (CB1001, Calbiochem, Darmstadt, Germany). Secondary antibodies used were anti-rabbit HRP (horseradish peroxidase) and anti-mouse HRP (Cell Signaling Inc., Danvers, MA, USA).
Cell viability assay
The viability of transfected cells was assayed using the Cell Titer Glo Cell Viability Assay (Promega, Madison, WI, USA) in opaque-walled multiwell plates (Costar, Baar, Germany). At 24, 48 and 72 h after transfection, an aliquot of 100 ml of cell suspension was assayed for its adenosine triphosphate content according to the manufacturer's instructions. Each assay was carried out in triplicate. An integration time of 0.3 s per well was used.
NFkB reporter assay
The firefly luciferase plasmid containing six binding sites for nuclear factor kappa B (NFkB) and the renilla luciferase plasmid were obtained as generous gifts from Professor Bernd Doerken (Max Delbrueck Center, Berlin, Germany). Cells were transfected with 500 nM siRNAs targeting or 1.25 mg of the plasmids coding for CCDC50, together with 0.83 mg of firefly-luciferase reporter plasmid and 0.42 mg of renilla-luciferase reporter plasmid. At 24 h after transfection, tumor necrosis factor-a (TNFa) induction (50 ng/ml) was performed. Immediately (0 h), 3 and 6 h after TNFa induction, luciferase activities of firefly and renilla were assayed with a luminometer (LB-940 Mithras Multilabel Reader, Berthold Technologies, Bad Wildbach, Germany), using a Dual-Luciferase Reporter System (Promega).
Results
Expression profiling revealed 72 overexpressed genes in frequently gained regions
Transcriptomes of 6 primary MCL and 18 primary CLL patient samples, as well as 6 cell lines, were profiled to identify overexpressed genes. The gene expression of cell lines was normalized to the lymphoblastoid non-tumor cell line LCL-WEI, whereas the gene expression of primary MCL and CLL cells was normalized to a pool of CD19 þ -sorted B cells from healthy donors. Results were compared with recent publications and revealed 37 novel and 35 predicted candidate genes (Supplementary Information, Supplementary Table S7 ). These genes are highly expressed and map to the respective gained chromosomal regions in MCL and CLL: 27 genes on chromosome bands 3q25-q29, 32 genes on bands 12q13-q14 and 13 genes on bands 18q21-q22 ( Table 1) .
Loss of function screen revealed 18 candidate genes
A total of 72 overexpressed genes were functionally analyzed in a transient RNA interference screen in MCL cell lines showing the respective chromosomal gain in 3q25-q29 (JVM-2), 12q13-q14 (JVM-2) or 18q21-q22 (Granta-519). For all functional assays, negative controls, such as scrambled siRNAs and siRNAs directed against firefly luciferase, were tested for unspecific effects on cell viability. Two assays were used as read out of the screen after functional gene knockdown: a luminescent-based cell viability assay (Figure 1 ) and FACS analysis (not shown). A direct correlation between cell viability and cell vitality was observed (not shown). The siRNAs directed against CCND1, KIF11, DUSP5, PLK1 and BCL2 served as positive controls. After the silencing of these genes, cell viability of MCL cell lines was reduced to 30-80%. For each of the 72 genes, a pool consisting of four siRNA sequences was transfected into MCL cell lines. After their transient knockdown, 18 genes revealed a reduction of cell viability when compared with negative controls.
CCDC50, SERPINI2 and SMARCC2 affect cell survival 
CCDC50 is overexpressed in MCL and CLL
The CCDC50 transcript expression was analyzed in B-cell neoplasia cell lines, as well as in primary MCL and CLL cells. The quantitative realtime PCR (qRT-PCR) experiments that were conducted with 16 lymphoma cell lines, comprising Burkitt's lymphoma, Hodgkin's lymphoma, diffuse large BCL, MCL and CLL (Figure 3a) , revealed an increased expression of CCDC50 only in MCL and CLL cells (ranging from 1.3-to 2.9-fold), except for the cell line Jeko-1. The qRT-PCR experiments with primary cells showed that 5 out of 8 MCL patients and 24 out of 28 CLL patients showed an upregulation of CCDC50 ranging from 1.5-to 10-fold, with a mean expression of 3.4-fold (MCL) and 3.5-fold (CLL) and a threshold of 1.5-fold overexpression, when compared with CD19 þ -selected B cells of healthy donors (Figure 3b ).
Silencing of CCDC50 inhibits survival
To validate the reduction of cell viability after transient CCDC50 gene knockdown, we determined the silencing effect of three independent siRNAs (siCCDC50 1, siCCDC50 2 and siCCDC50 3) in the cell line JVM-2. All siRNAs that were tested showed a significant RNA knockdown of 35-83% at 48 h post transfection (p.t.). The siCCDC50 2 and 3 revealed a decrease in cell viability to 51 and 44% at 72 h p.t. (Supplementary Figure S2) . We generated cell lines of the CLL and MCL origin (Mec-1 and JVM-2), in which CCDC50 was stably silenced by the genomic introduction of a short hairpin RNA coding vector. As shown by the results obtained from qRT-PCR experiments, the wild-type JVM-2 and Mec-1 cell lines showed a 2.9-and a 2.0-fold CCDC50 overexpression, respectively (Figure 3a) . CCDC50 RNA levels were reduced after stable CCDC50 silencing by 50% (JVM2 þ sh_CCDC50 1 and 3) and 80% (Mec1 þ sh_CCDC50 1) when compared with their parental cell lines (Figure 4a ), accompanied by reduced protein levels (Figure 4b ) and reduced Table 1 Overexpressed candidate genes on chromosome bands 3q25-q29, 12q13-q14 and 18q21-q22 RARRES1  3q25  IRAK3  12q13  PIAS2  18q21  PFN2  3q25  SLC38A2  12q13  IER3IP1  18q21  GPR160  3q26  HOXC6  12q13  RKHD2  18q21  ACTL6A  3q26  RAPGEF3  12q13  NARS  18q21  USP13  3q26  KIAA0286  12q13  TXNL1  18q21  BCHE  3q26  ARHGAP9  12q13  MALT1  18q21  APOD  3q26  DDIT3  12q13  BCL2  18q21  PIK3CA  3q26  MBD6  12q13  VPS4B  18q21  SerpinI2  3q26  RHEBL1  12q13  ZNF532  18q21  ECT2  3q26  TIMELESS  12q13  SerpinB2  18q21  SMC4  3q26  SMARCC2  12q13  CCDC5  18q21  YEATS2  3q27  RARG  12q13  TCF4  18q21  RFC4  3q27  STAT6  12q13  ZADH2  18q22  ECE2  3q27  CDK2  12q13  C3ORF40  3q27  FAM112B  12q13  DVL3  3q27  PA2G4  12q13  KLHL6  3q27  FAM113B  12q13  ETV5  3q28  ITGB7  12q13  LEPREL1  3q28  INHBE  12q13  FLJ42393  3q28  GLI1  12q13  CCDC50  3q29  MYL6B  12q13  LAMP3  3q29  METTL1  12q13  FAM43A  3q29  DTX3  12q13  C3orf34  3q29  DGKA  12q13  RPL39L  3q29  TUBA1B  12q13  PAK2  3q29  PTGES3  12q13  LRCH3  3q29  GDF11  12q13  CDK4  12q14  FAM119B  12q14  MARCH-IX  12q14  TSFM  12q14  KUB3 Low NFkB inducibility in CCDC50-silenced cells CCDC50, also known as Ymer, was previously identified in HeLa cells as a suppressor of NFkB activity through its interaction with the NFkB inhibitor, tumor necrosis factor, alpha-inducing protein 3 (TNFAIP3) 36, 37 To elucidate a possible downstream effect of CCDC50 expression, NFkB luciferase reporter assays were carried out. Therefore, we used HEK-293T cells because they combine the following three major advantages: (1) a high transfection efficiency, (2) a high inducibility of the NFkB reporter by TNFa (sevenfold) and (3) a 9.3-fold lower CCDC50 expression level than that of JVM-2 cells. NFkB reporter plasmids were transfected together with either a siRNA targeting CCDC50 or an expression construct coding for CCDC50. Twenty-four hours after transfection, NFkB activity was induced by TNFa and measured immediately, as well as 3 and 6 h after induction. After normalizing the activity of the firefly luciferase to the activity of the renilla luciferase, our results showed a direct correlation between inducibility and CCDC50 expression. High CCDC50 expression levels revealed a 16-fold NFkB induction by TNFa, whereas low CCDC50 expression levels only revealed a 6-to 7-fold induction ( Figure 6 ).
Genome-wide expression changes after CCDC50 modification
To investigate genome-wide gene expression changes, CCDC50 was transiently silenced by siCCDC50 3 or overexpressed by the plasmid pCMV_CCDC50 in MCL cell lines, JVM-2 and Granta-519. Seventy-two hours after transfection, the expression changes were analyzed using the Illumina expression array platform (Illumina Inc, San Diego, CA, USA) (Supplementary Figure S3) . Expression array results were normalized to transfection of cells with negative controls, such as siRNA non-template control or plasmid pCMV. Expression profiling in the cell line JVM-2 revealed a total of 28 deregulated genes (17 upregulated and 11 downregulated) and 58 aberrantly expressed genes (39 upregulated and 19 downregulated) in the cell line Granta-519 (Supplementary Tables S8 and S9) . Among the deregulated genes, a majority of genes were involved in p53 signaling pathways, as well as in the control of cell cycle progression and apoptosis. In JVM-2 and Granta-519, the genes TP53I3, CDKN1A and FDXR showed inverse expression levels when compared with CCDC50. Among the differentially expressed genes that were observed only in the cell line JVM-2 were PRODH, LAMP3, FAM129A, MAD4 and SENS1, which are involved in the control of cell cycle progression and apoptosis, whereas genes found differentially expressed only in Granta-519 were PHLDA3, GADD45A, BAX and RARRES3. Among the downregulated genes in JVM-2 after CCDC50 silencing were BNIP3L and LGMN, as well as BRWD1 and MDM4 in the cell line Granta-519. We identified TP53I3 as a significantly regulated gene in JVM-2 and Granta-519, showing an inverse expression status compared with that of CCDC50.These results indicate a role of CCDC50 in p53 signaling pathways.
Discussion
The expression analysis of genes located in commonly gained chromosomal regions 3q25-q29, 12q13-q14 and 18q21-q22 revealed 72 overexpressed genes in MCL and CLL. Silencing of these genes in a limited RNA interference screen identified 18 candidates that affect cell survival in the MCL cell line, JVM-2.
Out of these, CCDC50, SERPINI2 and SMARCC2 controlled cell viability also in primary CLL cells. As CCDC50 showed the most prominent effect on patient cells, it was further functionally characterized. NFkB reporter assays and genome-wide expression profiling studies showed an effect of CCDC50 on NFkB and p53 signaling pathways.
In the RNA interference screen, 18 candidate genes have been identified, of which 12 were novel and 6 have previously been associated with MCL or CLL: CCDC50, 8  6  7  3  1  2  44  15  39  12  21  16  14  32  9  35  5  34  40  29  11  25  37  26  6  18  30  41  28  7  22  19  48 Figure S1c) . Offtarget effects of single siRNA molecules, as well as technical limitations, may have contributed to the false positives and negatives, wherein the loss of cell viability could not be validated in the majority of tested individual siRNA sequences in cell lines. Such effects are key limitations in respective screening approaches, as siRNAs may produce a 'signature' of inhibited transcripts in addition to the intended targets. [42] [43] [44] CCDC50 was earlier identified to be overexpressed in MCL cells in comparison with other lymphomas 22, 39 and with benign reactive lymph node tissue of MCL patients. 38 We showed that MCL and CLL cell lines with a stable CCDC50 knockdown revealed 75% less proliferation than the parental cell lines (Figure 4a ). Recent publications reported an involvement of CCDC50 in NFkB and epidermal growth factor receptor signaling pathways. 45, 36, 37 CCDC50 is phosphorylated and ubiquitinated on epidermal growth factor stimulation and inhibits epidermal growth factor receptor downregulation. 44 On the basis of investigations conducted in HeLa cells, CCDC50 was postulated as a negative regulator of the NFkB pathway. 36, 37 CCDC50 was found to interact with TNFAIP3, 46 which acts as a negative feedback regulator of NFkB and decreases NFkB signaling. 46, 47 Interestingly, our data showed a survival-stimulating effect of CCDC50 in MCL and CLL cells, which might be mediated by enhanced NFkB signaling and implicate that the influence of CCDC50 on cell viability might be cell-type specific. Recent literature reported that TNFa induced NFkB activation is leading to the survival of MCL and CLL cells. [46] [47] [48] In this study, we showed that the TNFa stimulation of the NFkB reporter plasmid revealed a 56% less inducibility in human embryonic kidney 293-T (HEK-293T) cells, transiently silenced for CCDC50, compared with cells with CCDC50 overexpression (Figure 6 ). These findings, as well as cell viability assays carried out in MCL and CLL cells, support our hypothesis that CCDC50 has a survival-stimulating effect. Low CCDC50 expression levels correlated with reduced cell viability, which may be caused by low NFkB inducibility.
Genome-wide expression changes after CCDC50 modulation discovered genes mainly involved in the p53 signaling pathway (BAX, CDKN1A, FDXR, GADD45A, LAMP3, PRODH, PHLDA3, SESN1 and TP53I3), as well as those involved in the inhibition of cell cycle progression and the induction of apoptosis (FAM129A, MAD4 and RARRES3).
49-55 BAX, GAD-D45A, CDKN1A and SESN1 were previously reported as direct Tumor necrosis factor-a (TNFa) induction in HEK-293T cells was performed 24 h after transfection of the two reporter plasmids. NFkB reporter activity was measured before (0 h), as well as 3 and 6 h after TNFa induction. Normalization was performed when comparing the activity of the firefly luciferase with the activity of the renilla luciferase. Finally, fold induction was calculated as a correlation between TNFa-induced cells and uninduced cells. HEK-293T; human embryonic kidney 293-T cell line. p53 target genes. 56 Among the downregulated genes were BNIP3L and LGMN (JVM-2), as well as MDM4 and BRWD1 (Granta-519). These genes have previously been identified in cell cycle progression and p53 pathways. [49] [50] [51] [52] [53] [54] [55] TP53I3 is described as an oxidoreductase that acts in p53-mediated apoptosis. MCL and CLL cells show, after CCDC50 silencing, increased TP53I3 expression levels and reduced cell viability. Increased inducibility of TP53I3 could be protective against cancer because cells might more readily undergo apoptosis after stress. Further studies revealed mir-34a as a novel target of p53 in primary CLL cells. 24, 57 Reduction of mir-34a expression was associated with increased cell viability after DNA damage. Upregulation of mir-34a induced the expression of BAX and p21.
24,57 As we identified an overexpression of BAX and p21, as well as a reduction of cell viability after CCDC50 silencing, we postulated an involvement of CCDC50 in p53 signaling pathways.
In summary, the reduction of cell viability after CCDC50 silencing might be explained by the overexpression of apoptosis-stimulating genes involved in the p53 signaling pathways as well as by the downregulation of apoptosis-protecting genes. Moreover, the involvement of CCDC50 in NFkB signaling pathways may have major effects on cell survival.
Conclusions
Expression profiling of primary MCL and CLL cells identified 72 upregulated genes in recurrently gained regions 3q, 12q and 18q. Knockdown of these genes applying a siRNA screen revealed for CCDC50, SERPINI2 and SMARCC2 a reduction of cell viability in primary CLL cells as well as in cell lines. Stable silencing of CCDC50 inhibited cell proliferation in MCL and CLL cell lines. Furthermore, our data indicated that CCDC50 has an important function in TNFa-induced NFkB signaling.
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